Literature DB >> 16123597

DeltaNp63alpha levels correlate with clinical tumor response to cisplatin.

Rachel Zangen1, Edward Ratovitski, David Sidransky.   

Abstract

After exposure to damaging agents, the p53 tumor suppressor is stabilized mediating cell cycle arrest and apoptosis. p53 family member, DeltaNp63 promotes cell proliferation and accelerates tumor growth. We previously found that the genotoxic stress agents induced a decrease of DeltaNp63alpha. We further observed that genotoxic stress mediated phosphorylation of DeltaNp63alpha targeting it into proteasome degradation. Here, we found that high DeltaNp63 protein levels in primary tumors accurately predicted response to platinum based chemotherapy and a favorable outcome in head and neck cancer patients. Our data suggest that degradation of DeltaNp63alpha is part of the cellular response to DNA damage in head and neck cancers. The findings may have implications for the rational use of DNA damaging agents in human cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16123597     DOI: 10.4161/cc.4.10.2066

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  37 in total

1.  Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.

Authors:  Wusheng Yan; Ignacio I Wistuba; Michael R Emmert-Buck; Heidi S Erickson
Journal:  Am J Cancer Res       Date:  2011-01-01       Impact factor: 6.166

2.  TNF-α promotes c-REL/ΔNp63α interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancer.

Authors:  Hai Lu; Xinping Yang; Praveen Duggal; Clint T Allen; Bin Yan; Jonah Cohen; Liesl Nottingham; Rose-Anne Romano; Satrajit Sinha; Kathryn E King; Wendy C Weinberg; Zhong Chen; Carter Van Waes
Journal:  Cancer Res       Date:  2011-09-20       Impact factor: 12.701

Review 3.  Therapeutic prospects for p73 and p63: rising from the shadow of p53.

Authors:  Anna Vilgelm; Wael El-Rifai; Alexander Zaika
Journal:  Drug Resist Updat       Date:  2008-09-17       Impact factor: 18.500

4.  p63 and Ki-67 immunostainings in laryngeal squamous cell carcinoma are related to survival.

Authors:  M Re; A Zizzi; L Ferrante; D Stramazzotti; G Goteri; F M Gioacchini; F Olivieri; G Magliulo; C Rubini
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-01-09       Impact factor: 2.503

5.  Phospho-ΔNp63α is a key regulator of the cisplatin-induced microRNAome in cancer cells.

Authors:  Y Huang; A Chuang; H Hao; C Talbot; T Sen; B Trink; D Sidransky; E Ratovitski
Journal:  Cell Death Differ       Date:  2011-01-28       Impact factor: 15.828

Review 6.  Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.

Authors:  Juan Jin; Wenwen Zhang; Wenfei Ji; Fang Yang; Xiaoxiang Guan
Journal:  Cancer Biol Ther       Date:  2017-05-11       Impact factor: 4.742

7.  Expression and regulation of the ΔN and TAp63 isoforms in salivary gland tumorigenesis clinical and experimental findings.

Authors:  Yoshitsugu Mitani; Jie Li; Randal S Weber; Scott L Lippman; Elsa R Flores; Carlos Caulin; Adel K El-Naggar
Journal:  Am J Pathol       Date:  2011-05-07       Impact factor: 4.307

8.  Impaired repair of cyclobutane pyrimidine dimers in human keratinocytes deficient in p53 and p63.

Authors:  Bridget E Ferguson-Yates; Hongyan Li; Tiffany K Dong; Jennifer L Hsiao; Dennis H Oh
Journal:  Carcinogenesis       Date:  2007-11-04       Impact factor: 4.944

9.  ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage.

Authors:  Yiping Huang; Tanusree Sen; Jatin Nagpal; Sunil Upadhyay; Barry Trink; Edward Ratovitski; David Sidransky
Journal:  Cell Cycle       Date:  2008-09-15       Impact factor: 4.534

10.  Phospho-ΔNp63α/microRNA feedback regulation in squamous carcinoma cells upon cisplatin exposure.

Authors:  Yiping Huang; Dafna Kesselman; Darya Kizub; Rafael Guerrero-Preston; Edward A Ratovitski
Journal:  Cell Cycle       Date:  2013-01-23       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.